Acute Myeloid Leukemia

New survival data on Evoltra (clofarabine) in elderly leukemia patients reported

Published in Cancer Weekly, August 1st, 2006

Bioenvision (BIVN) announced new data from its BIOV-121 nonrandomized phase II clinical study that based upon historical controls suggests single agent Evoltra (clofarabine) is as effective as intensive chemotherapy in elderly patients with adverse cytogenetics.

Professor Alan Burnett Chairman of the UK National Cancer Research Institute Hematological Study Group said, "Clofarabine was able to, at least, match the treatment outcome in patients who are fit for intensive chemotherapy and, importantly does not cause alopecia and mucositis, side effects typically seen with intensive treatment."

The clofarabine data was from BIOV-121, Bioenvision's acute...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry